Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 101 to 110 of 899

TitleReference numberPublishedLast updated
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)TA1061
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTA1057
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Cladribine for treating active relapsing forms of multiple sclerosisTA1053
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTA1051
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050

Results per page

  1. 10
  2. 25
  3. 50
  4. All